NCT07432386Not yet recruitingPhase 4
Methotrexate Versus Apremilast for Pruritus in Psoriasis
Comparison of Efficacy of Methotrexate Versus Apremilast in the Treatment of Pruritus in Psoriasis: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 19 Feb 2026
- Start date
- 14 May 2026
- Primary completion date
- 14 Oct 2026
- Lead sponsor
- Zarmeen Khawar
- Diseases
- Psoriasis
- NCT number
- NCT07432386
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 80
- From 14 May 2026 to the primary completion date, 14 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently receiving systemic therapy for psoriasis within the last 4 weeks.
Other illness
- Patients with severe hepatic or renal impairment.
- Patients with known hypersensitivity to Methotrexate or Apremilast.
- Patients with active infections, including tuberculosis.
- Patients with malignancy.
Other
- \- Pregnant or lactating women.
- Patients with significant hematological abnormalities.
- Patients unwilling to provide informed consent.
Who the study is looking for
- Male and female patients aged 18 to 65 years.
- Clinically diagnosed cases of psoriasis.
- Patients experiencing pruritus associated with psoriasis.
- Patients willing to participate and provide written informed consent.
- Patients able to comply with study protocol and follow-up visits.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pak Emirates Military Hospital Coordinator of this site? Confirm its status | Rawalpindi | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.